• Innate Pharma completed dose-escalation enrollment in its phase 1 IPH4502-101 trial for Nectine-4 ADC IPH4502.
• Preliminary data on 76 patients expected by year-end to set dose-optimization plans in selected solid tumors.
• Early readout showed a favorable safety profile to date, with limited hematologic toxicity.
• Objective responses reported in heavily pretreated urothelial cancer post-enfortumab vedotin, non-small cell lung cancer, head and neck squamous cell carcinoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.